Osimertinib induces paraptosis and TRIP13 confers resistance in glioblastoma cells

Osimertinib induces paraptosis and TRIP13 confers resistance in glioblastoma cells

Abstract The efficacy of osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, has been evaluated in glioblastoma (GBM) through preclinical and clinical trials. However, the underlying mechanism of osimertinib-induced GBM cell death and the underlying resistance...

Full description

Bibliographic Details
Main Authors: Lulu Hu, Ji Shi, Dachuan Shen, Xingyue Zhai, Dapeng Liang, Jing Wang, Chunrui Xie, Zhiyu Xia, Jing Cui, Feng Liu, Sha Du, Songshu Meng, Haozhe Piao
Format: Article
Language:English
Published: Nature Publishing Group 2023-09-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-023-01632-6

Internet

https://doi.org/10.1038/s41420-023-01632-6

Similar Items